Modotuximab (Anti-ERBB1 / EGFR / HER1) is a recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. MW: 146.6 KD.